Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - Praxis Precision Medicines reported a quarterly loss of $2.94 per share, slightly better than the Zacks Consensus Estimate of a loss of$ 2.96, and an improvement from a loss of $2.97 per share a year ago, indicating an earnings surprise of 0.68% [1] - The company achieved revenues of$ 7.46 million for the quarter ended December 2024, significantly surpassing the Zacks Consensus Estimate by 1,467.86%, compared to revenues of $0.52 million in the same quarter last year [2] - The stock has underperformed, losing about 15.5% since the beginning of the year, while the S&P 500 has declined by only 0.3% [3] Group 2 - The earnings outlook for Praxis Precision Medicines is mixed, with the current consensus EPS estimate for the coming quarter at -$ 2.80 on $0.5 million in revenues, and -$ 12.22 on $1.91 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8] - Atara Biotherapeutics, a peer in the same industry, is expected to report a quarterly loss of$ 3.82 per share, reflecting a year-over-year change of +72.7%, with revenues projected to be $13.1 million, up 208.2% from the previous year [9]